View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
March 23, 2021updated 12 Jul 2022 11:21am

Country trends for Covid-19 clinical trials

As the world tries to come back to normal from the COVID-19 pandemic, although some vaccines have already received Emergency Use Authorizations (EUAs), including those developed by Pfizer and Moderna, many companies and organizations continue to run clinical trials to find vaccines and therapeutics for COVID-19.

By GlobalData Healthcare

As the world tries to come back to normal from the COVID-19 pandemic, although some vaccines have already received Emergency Use Authorizations (EUAs), including those developed by Pfizer and Moderna, many companies and organizations continue to run clinical trials to find vaccines and therapeutics for COVID-19. GlobalData continues to gather and analyze those COVID-19 clinical trials since the beginning of the pandemic.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Overall, the number of COVID-19 clinical trials continues to increase into 2021. As of March 8, 2021, clinical trials in the US continue to greatly outnumber those in other countries. Currently, the US has 823 clinical trials, almost double that of India, which is second with 491 clinical trials. China, Iran, and Spain round out the top five, all of which have more than 200 COVID-19 clinical trials. China has had the slowest increase, which can be seen in Figure 1 below. The number of clinical trials for China slowly increased from 318 to 488 over the course of the pandemic, an almost flat line compared to the US and India.

With the number of COVID-19 clinical trials continuing to rise all over the world, analysis will continue to clarify which countries will have the most trials. While the US will continue to dominate, India expects to continue to increase their number of clinical trials, as seen with the steep increase in the graph below.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena